Tumour-stroma interactions in pancreatic ductal adenocarcinoma: Rationale and current evidence for new therapeutic strategies

Cancer Treatment Reviews

Volumn 40, Issue 1, 2014, Pages 118-128

  Heinemann, V ^a   Reni, M ^b   Ychou, M ^c   Richel, D J ^d   Macarulla, T ^e   Ducreux, M ^f  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c CENTRE VAL D AURELLE   (France)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Extracellular matrix; Gemcitabine; Nab paclitaxel; Pancreatic cancer; Sonic hedgehog; SPARC; Stellate cells; Stem cells; Stroma

Indexed keywords

CAPECITABINE; CD40 ANTIGEN; CYCLOPAMINE; DOVITINIB; ERLOTINIB; FGK 45; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HUMAN RECOMBINANT PH20 HYALURONIDASE; HYALURONIDASE; IRINOTECAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY FGK45; OSTEONECTIN; OXALIPLATIN; PACLITAXEL; SARIDEGIB; SONIC HEDGEHOG PROTEIN; SONIDEGIB; UNCLASSIFIED DRUG; VANDETANIB; VISMODEGIB;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMORADIOTHERAPY; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPOCALCEMIA; INTESTINE LIPODYSTROPHY; LEUKOPENIA; MAXIMUM TOLERATED DOSE; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STROMA; THROMBOCYTOPENIA; TISSUE INTERACTION; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

EXTRACELLULAR MATRIX; GEMCITABINE; NAB-PACLITAXEL; PANCREATIC CANCER; SONIC HEDGEHOG; SPARC; STELLATE CELLS; STEM CELLS; STROMA;

ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; DEOXYCYTIDINE; HUMANS; PACLITAXEL; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84887076296     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.04.004     Document Type: Review

References (98)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Simard E.P., Ward E.M., Siegel R., Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012.
3. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J Clin 2012, 62:10-29.
4. Malvezzi M., Bertuccio P., Levi F., La Vecchia C., Negri E. European cancer mortality predictions for the year 2012. Ann Oncol 2012, 23:1044-1052.
5. National Cancer Institute Surveillance Epidemiology and End Results (SEER) Stat Fact Sheets: Pancreas 2012. Available at: < (accessed 26.01.2012). http://seer.cancer.gov/statfacts/html/pancreas.html.
6. ACS American Cancer Society Cancer facts and figures 2011, 2012. Available at: < (accessed 28.02.2012). http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf.
7. Cascinu S., Falconi M., Valentini V., Jelic S. Pancreatic cancer: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v55-v58.
8. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma Version 2. 2012. Available at: <(accessed 26.01.2012). http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.
9. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
10. Cunningham D., Chau I., Stocken D.D., Valle J.W., Smith D., Steward W., et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009, 27:5513-5518.
11. Heinemann V., Quietzsch D., Gieseler F., Gonnermann M., Schonekas H., Rost A., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006, 24:3946-3952.
12. Louvet C., Labianca R., Hammel P., Lledo G., Zampino M.G., Andre T., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005, 23:3509-3516.
13. Reni M., Cordio S., Milandri C., Passoni P., Bonetto E., Oliani C., et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005, 6:369-376.
14. Heinemann V., Haas M., Boeck S. Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev 2012, [epub ahead of print].
15. Heinemann V., Boeck S., Hinke A., Labianca R., Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008, 8:82.
16. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-1966.
17. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825.
18. Ko A.H. FOLFIRINOX: a small step or a great leap forward?. J Clin Oncol 2011, 29:3727-3729.
19. Pancreatic section of the British Society of Gastroenterology, PSoGB and Ireland AoUGSoGBaI, Royal College of Pathologists SIGfG-IR. Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut 2005, 54(Suppl. 5):v1-v16.
20. Ishii H., Furuse J., Nakachi K., Suzuki E., Yoshino M. Primary tumor of pancreatic cancer as a measurable target lesion in chemotherapy trials. Jpn J Clin Oncol 2005, 35:601-606.
21. Reni M., Cereda S., Balzano G., Passoni P., Rognone A., Fugazza C., et al. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 2009, 115:2630-2639.
22. Jimeno A., Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther 2006, 5:787-796.
23. Bachet J.B., Marechal R., Van Laethem J.L. Treatment of pancreatic cancer: what can we really predict today?. Cancers 2011, 3:675-699.
24. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat Med 2004, 10:789-799.
25. Zavoral M., Minarikova P., Zavada F., Salek C., Minarik M. Molecular biology of pancreatic cancer. World J Gastroenterol 2011, 17:2897-2908.
26. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
27. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362:1605-1617.
28. Mahadevan D., Von Hoff D.D. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007, 6:1186-1197.
29. Hidalgo M., Maitra A. The hedgehog pathway and pancreatic cancer. N Engl J Med 2009, 361:2094-2096.
30. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., et al. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67:1030-1037.
31. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
32. Hermann P.C., Huber S.L., Heeschen C. Metastatic cancer stem cells: a new target for anti-cancer therapy?. Cell Cycle 2008, 7:188-193.
33. Subramaniam D., Ramalingam S., Houchen C.W., Anant S. Cancer stem cells: a novel paradigm for cancer prevention and treatment. Mini Rev Med Chem 2010, 10:359-371.
34. Erkan M., Reiser-Erkan C., Michalski C.W., Kong B., Esposito I., Friess H., et al. The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance. Curr Mol Med 2012, 12:288-303.
35. Kleeff J., Beckhove P., Esposito I., Herzig S., Huber P.E., Lohr J.M., et al. Pancreatic cancer microenvironment. Int J Cancer 2007, 121:699-705.
36. Jaster R. Molecular regulation of pancreatic stellate cell function. Mol Cancer 2004, 3:26.
37. Erkan M., Reiser-Erkan C., Michalski C.W., Deucker S., Sauliunaite D., Streit S., et al. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia 2009, 11:497-508.
38. Erkan M., Reiser-Erkan C., Michalski C.W., Kleeff J. Tumor microenvironment and progression of pancreatic cancer. Exp Oncol 2010, 32:128-131.
39. Omary M.B., Lugea A., Lowe A.W., Pandol S.J. The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest 2007, 117:50-59.
40. Arnold S.A., Brekken R.A. SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal 2009, 3:255-273.
41. Fujita T., Shiba H., Sakata M., Uchida Y., Nakamura S., Kurihara H. SPARC stimulates the synthesis of OPG/OCIF, MMP-2 and DNA in human periodontal ligament cells. J Oral Pathol Med 2002, 31:345-352.
42. Sasaki T., Hohenester E., Gohring W., Timpl R. Crystal structure and mapping by site-directed mutagenesis of the collagen-binding epitope of an activated form of BM-40/SPARC/osteonectin. EMBO J 1998, 17:1625-1634.
43. Sage H., Vernon R.B., Funk S.E., Everitt E.A., Angello J. SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca+2-dependent binding to the extracellular matrix. J Cell Biol 1989, 109:341-356.
44. Francki A., McClure T.D., Brekken R.A., Motamed K., Murri C., Wang T., et al. SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. J Cell Biochem 2004, 91:915-925.
45. Hasselaar P., Sage E.H. SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J Cell Biochem 1992, 49:272-283.
46. Kupprion C., Motamed K., Sage E.H. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem 1998, 273:29635-29640.
47. Motamed K., Funk S.E., Koyama H., Ross R., Raines E.W., Sage E.H. Inhibition of PDGF-stimulated and matrix-mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin-dependent kinase inhibitors. J Cell Biochem 2002, 84:759-771.
48. Bradshaw A.D. The role of SPARC in extracellular matrix assembly. J Cell Commun Signal 2009, 3:239-246.
49. Bradshaw A.D., Francki A., Motamed K., Howe C., Sage E.H. Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation. Mol Biol Cell 1999, 10:1569-1579.
50. Guweidhi A., Kleeff J., Adwan H., Giese N.A., Wente M.N., Giese T., et al. Osteonectin influences growth and invasion of pancreatic cancer cells. Ann Surg 2005, 242:224-234.
51. Infante J.R., Matsubayashi H., Sato N., Tonascia J., Klein A.P., Riall T.A., et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007, 25:319-325.
52. Mantoni T.S., Schendel R.R., Rodel F., Niedobitek G., Al-Assar O., Masamune A., et al. Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biol Ther 2008, 7:1806-1815.
53. Sage H., Johnson C., Bornstein P. Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. J Biol Chem 1984, 259:3993-4007.
54. Trieu V., Frankel T., Labao E., Soon-Shiong P., Desai N. SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol. Proc Amer Assoc Cancer Res 2005, 46. (Abstract 5584).
55. Chlenski A., Guerrero L.J., Salwen H.R., Yang Q., Tian Y., Morales La Madrid A., et al. Secreted protein acidic and rich in cysteine is a matrix scavenger chaperone. PLoS One 2011, 6:e23880.
56. Liddelow S.A., Dziegielewska K.M., Mollgard K., Phoenix T.N., Temple S., Vandeberg J.L., et al. SPARC/osteonectin, an endogenous mechanism for targeting albumin to the blood-cerebrospinal fluid interface during brain development. Eur J Neurosci 2011, 34:1062-1073.
57. Liddelow S.A., Temple S., Mollgard K., Gehwolf R., Wagner A., Bauer H., et al. Molecular characterisation of transport mechanisms at the developing mouse blood-CSF interface: a transcriptome approach. PLoS One 2012, 7:e33554.
58. Di Marco M., Macchini M., Vecchiarelli S., Sina S., Biasco G. Hedgehog signaling: from the cuirass to the heart of pancreatic cancer. Pancreatology 2012, 12:388-393.
59. Feldmann G., Habbe N., Dhara S., Bisht S., Alvarez H., Fendrich V., et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008, 57:1420-1430.
60. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
61. Jimeno A., Feldmann G., Suarez-Gauthier A., Rasheed Z., Solomon A., Zou G.M., et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 2009, 8:310-314.
62. Khan G.N., Griffith K., Greenson J., Takebe N., Zalupski M., Simeone D., et al. Cancer stem cells (CSC) and inhibition of hedgehog (Hh) pathway signaling in advanced pancreatic cancer: GDC-0449 in combination with gemcitabine (Gem). American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference 2012 June, Lake Tahoe, Nevada, USA, 2012.
63. Palmer S.R., Erlichman C., Fernandez-Zapico M., Qi Y., Almada L., McCleary-Wheeler A., et al. Phase I trial erlotinib gemcitabine and the hedgehog inhibitor GDC-0449. J Clin Oncol 2011, 29(Suppl.). (Abstract 3092).
64. Richards D.A., Stephenson J., Wolpin B.M., Becerra C., Turner Hamm J., Messersmith W.A., et al. A phase Ib trial of IPI-926 a hedgehog pathway inhibitor plus gemcitabine in patients with metastatic pancreatic cancer. J Clin Oncol 2012, 30(Suppl. 4). (Abstract 213).
65. Infinity Pharmaceuticals. Infinity Reports Update from Phase 2 Study of Saridegib Plus Gemcitabine in Patients with Metastatic Pancreatic Cancer. in press. Available at: (accessed 26.03.2013). http://phx.corporate-ir.net/phoenix.zhtml?c=121941&p=irol-newsArticle&ID=1653550&highlight=.
66. Clark C.E., Hingorani S.R., Mick R., Combs C., Tuveson D.A., Vonderheide R.H. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007, 67:9518-9527.
67. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
68. Yokoi K., Sasaki T., Bucana C.D., Fan D., Baker C.H., Kitadai Y., et al. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res 2005, 65:10371-10380.
69. Hwang R.F., Yokoi K., Bucana C.D., Tsan R., Killion J.J., Evans D.B., et al. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 2003, 9:6534-6544.
70. Provenzano P.P., Cuevas C., Chang A.E., Goel V.K., Von Hoff D.D., Hingorani S.R. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:418-429.
71. Borad M.J., Ramanathan R.K., Bessudo A., LoRusso P., Shepard H.M., Maneval D.C., et al. Targeting hyaluronan (HA) in tumor stroma A phase I study to evaluate the safety pharmacokinetics (PK) and pharmacodynamics (PD) of pegylated hyaluronidase (PEGPH20) in patients with solid tumors. J Clin Oncol 2012, 30(Suppl.). (Abstract 2579).
72. Desai N. Nab technology: a drug delivery platform utilising endothelial gp60 receptor-based transport and tumour-derived SPARC for targeting. Drug Delivery, Report 2007/2008. 16th ed., 37-41.
73. Von Hoff D.D., Ramanathan R.K., Borad M.J., Laheru D.A., Smith L.S., Wood T.E., et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011, 29:4548-4554.
74. Frese K.K., Neesse A., Cook N., Bapiro T.E., Lolkema M.P., Jodrell D.I., et al. Nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discovery 2012, 28:2012. 10.1158/2159-8290.CD-11-0242.
75. Kulke M.H., Tempero M.A., Niedzwiecki D., Hollis D.R., Kindler H.L., Cusnir M., et al. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol 2009, 27:5506-5512.
76. Xenidis N., Chelis L., Amarantidis K., Chamalidou E., Dimopoulos P., Courcoutsakis N., et al. Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study. Cancer Chemother Pharmacol 2012, 69:477-484.
77. De Jesus-Acosta A., Oliver G.R., Blackford A., Kinsman K., Flores E.I., Wilfong L.S., et al. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2012, 69:415-424.
78. Fine R.L., Fogelman D.R., Schreibman S.M., Desai M., Sherman W., Strauss J., et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 2008, 61:167-175.
79. Katopodis O., Polyzos A., Kentepozidis N., Giassas S., Rovithi M., Bozionelou V., et al. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. Cancer Chemother Pharmacol 2011, 67:361-368.
80. Reni M., Cereda S., Rognone A., Belli C., Ghidini M., Longoni S., et al. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). Cancer Chemother Pharmacol 2012, 69:115-123.
81. Saif M.W., Syrigos K., Penney R., Kaley K. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. Anticancer Res 2010, 30:2905-2909.
82. Rougier P., Adenis A., Ducreux M., de Forni M., Bonneterre J., Dembak M., et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 2000, 36:1016-1025.
83. Ramanathan RK, Borad M, Laheru D, Smith LS, Wood TE, Korn RL, et al. Results of a phase 1/2 study of nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer with SPARC and CA19-9 correlatives. Ann Oncol 2010;21 (Suppl. 8):viii234 (abstract 743P). Available at: http://annonc.oxfordjournals.org/content/21/suppl_8/viii225.full.pdf+html.
84. El-Khoueiry A.B., Iqbal S., Lenz H., Gitlitz B.J., Yang D., Cole S., et al. A phase I study of two different schedules of nab-paclitaxel (nab-P) with ascending doses of vandetanib (V) with expansion in patients (Pts) with pancreatic cancer (PC). J Clin Oncol 2011, 29(Suppl.). (Abstract 4124).
85. Hosein P.J., de Lima Lopes G., Pastorini V.H., Gomez C., Macintyre J., Zayas G., et al. A Phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol 2012, 36:151-156.
86. NCT00844649. Phase III study of ABI-007(Albumin-bound Paclitaxel) plus gemcitabine vs. gemcitabine in metastatic adenocarcinoma of the pancreas (NCT00844649). Available at: (accessed 29.03.2012). http://clinicaltrials.gov/ct2/show/NCT00844649?term=NCT00844649&rank=1.
87. Von Hoff D.D., Ervin T.J., Arena F.P., Chiorean E.G., Infante J.R., Moore M.J., et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J Clin Oncol 2012, 30(Suppl. 34). (Abstract LBA148).
88. Socinski M.A., Bondarenko I., Karaseva N.A., Makhson A.M., Vynnychenko I., Okamoto I., et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012, 30:2055-2062.
89. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794-7803.
90. Hersh E., Del Vecchio M., Brown M., Kefford R., Loquai C., Testori A., et al. Phase 3, randomized, open-label, multicenter trial of nab-paclitaxel (nab-P) vs dacarbazine (DTIC) in previously untreated patients with metastatic malignant melanoma (MMM). Pigment Cell Melanoma Res 2012, 25:863.
91. Celgene Corporation. ABRAXANE® Plus Gemcitabine Demonstrates Significant Survival Advantage in Phase III Study of Patients with Advanced Pancreatic Cancer. 2012. Available at: (accessed 25.03.2013). http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1776848&highlight=.
92. NCT01088815. Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas (NCT01088815). Available at: < (accessed 29.03.2012). http://clinicaltrials.gov/ct2/show/NCT01088815?term=GDC-0449&cond=pancreatic+cancer&rank=5.
93. Schwartz D.L., Bankson J.A., Lemos R., Lai S.Y., Thittai A.K., He Y., et al. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther 2010, 9:2057-2067.
94. Reyal J. Arterial flow focalization could increase tissue oxygen partial pressure, or trigger endothelial shear stress - a new concept to overcome cancer hypoxia-induced radiotherapy resistance, or stimulate liver regeneration during fulminant hepatitis. Med Hypotheses 2010, 74:301-308.
95. Gillen S., Schuster T., Meyer Zum Buschenfelde C., Friess H., Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010, 7:e1000267.
96. Alvarez-Gallego R., Cubillo A., Rodriguez-Pascual J., Quijano Y., De Vincente E., Garcia L., et al. Antitumor activity of nab-paclitaxel and gemcitabine in resectable pancreatic cancer. J Clin Oncol 2012, 30(Suppl.). (Abstract 4040).
97. NCT00785291. Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer (NCT00785291). Available at: <(accessed 31.10.2011). http://clinicaltrials.gov/ct2/show/NCT00785291?term=40502&intr=abraxane&phase=2&rank=1.
98. NCT00864253. A Trial of ABI-007 vs. Dacarbazine in previously untreated patients with metastatic malignant melanoma (NCT00864253). Available at: < (accessed 31.10.2011). http://clinicaltrials.gov/ct2/show/NCT00864253?term=SPARC&intr=abraxane&phase=2&rank=1.